Skip to main content

Advertisement

SpringerLink
Log in

Systemic lupus Erythematosus and IgA multiple myeloma: a rare association?

  • CASE
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The coexistence of systemic lupus Erythematosus (SLE) and multiple myeloma (MM) is uncommon and the pathogenetic mechanisms underlying this association remain unclear. We report the case of a woman who was diagnosed with SLE in 1993 aged 57, then developing IgA lambda type MM in the IIB clinical stage 7 years later. The SLE was treated successfully with methylprednisolone and chloroquine, and low dose maintenance steroid was continued with bisphosphonate protection until December 1994 when she suffered multiple vertebral fractures. She continued to receive 4 mg alternate day methylprednisolone and calcitonin until she decided to discontinue her own treatment 2 years later. In 2000, while still in stable SLE remission, she was diagnosed with MM. Protein electrophoresis revealed the IgA lambda paraprotein (40.5 g/l) and she had a Bence Jones (BJ) proteinuria of the lambda light chain type. Bone marrow trephine biopsy revealed a massive patchy infiltrate of abnormal plasmocytes (70%), while an extensive x-ray skeletal survey did not show any new fractures or osteolysis. The patient was treated according to the VMCP protocol without attaining a plateau phase. There was a similar poor clinical response to second and third line treatments (VAD, Thalidomide, Melphalan, and high dose dexamethasome). After 4 years of refractory disease the patient died from severe bilateral pneumonia. This case is discussed with reference to the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pettersson T, Pukkala E, Teppo L, Friman C. Increase risk of cancer in patients with systemic lupus Erythematosus. Ann Rheum Dis 1992;51(4):437–9.

    PubMed  CAS  Google Scholar 

  2. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus Erythematosus. Arthritis Rheum 1996;39(6):1050–4.

    Article  PubMed  CAS  Google Scholar 

  3. Mellemkjaer L, et al. Non-Hodgkin′s lymphomas and other cancers among a cohort of patients with systemic lupus Erythematosus. Arthritis Rheum 1997;40(4):761–8.

    Article  PubMed  CAS  Google Scholar 

  4. Vineis P, et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health 2000;54(6):431–6.

    Article  PubMed  CAS  Google Scholar 

  5. Cibere J, Sibley J, Haga M. Systemic lupus Erythematosus and the risk of malignancy. Lupus 2001;10(6):394–400.

    Article  PubMed  CAS  Google Scholar 

  6. Xu Y, Wiernik PH. Systemic lupus Erythematosus and B-cell hematologic neoplasm. Lupus 2001;10(12):841–50.

    Article  PubMed  CAS  Google Scholar 

  7. Afeltra A, et al. Systemic lupus Erythematosus and multiple myeloma: a rare association. Semin Arthritis Rheum 1997;26(6):845–9.

    Article  PubMed  CAS  Google Scholar 

  8. Jordan E, Burnstein SL, Calabro JJ, Henderson ES. Multiple myeloma complicating the course of seronegative systemic lupus Erythematosus. Arthritis Rheum 1978;21(2):260–5.

    Article  PubMed  CAS  Google Scholar 

  9. Pehamberger M, Diem E, Konrad K. Systemic lupus Erythematosus with multiple myeloma. Acta Derm Venereol 1978;58(6):527–30.

    PubMed  CAS  Google Scholar 

  10. Solary E, et al. Systemic lupus Erythematosus occurring in a patient with multiple myeloma. Arthrtis Rheum 1986;29(7):933–4.

    Article  CAS  Google Scholar 

  11. Isobe T, Osserman EF. Pathologic conditions associated with plasma cell dyscrasias: a study of 806 cases. Ann N Y Acad Sci 1971;190:507–18.

    Article  PubMed  CAS  Google Scholar 

  12. Butler RC, Thomas SM, Thomson JM, Keat ACS. Anaplastic myeloma in systemic lupus Erythematosus. Ann Rheum Dis 1984;43:653–5.

    PubMed  CAS  Google Scholar 

  13. Sendagorta E, Matarredona J, Brieva JA, Rodriguez ML, Ledo A. Systemic lupus Erythematosus in association with smoldering multiple myeloma. J Am Acad Dermatol 1987;16(1 pt 1):135–6.

    PubMed  CAS  Google Scholar 

  14. Vaiopoulos G, Konstatopoulos K, Mantzourani M, Kaklamanis P. Multiple myeloma associated with systemic lupus Erythematosus. Leuk Lymphoma 2003;44(5):893–4.

    Article  PubMed  Google Scholar 

  15. Urbanska-Rys H, et al. Multiple myeloma in a patient with systemic lupus Erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma. Leuk Lymphoma 2004;45(9):1913–8.

    Article  PubMed  Google Scholar 

  16. Menon S, Snaith J, Isenberg DA. The association of malignancy with SLE.: an analysis of 150 patients under long term review. Lupus 1993;2(3):177–81.

    PubMed  CAS  Google Scholar 

  17. Munzert G, Frickhofen N, Bauditz J, Schreiber S, Herrmann F. Concomitant manifestations of systemic lupus Erythematosus and low-grade non-Hodgkin’s lymphoma. Leukemia 1997;11(8):1324–8.

    Article  PubMed  CAS  Google Scholar 

  18. Ramsey-Goldman R, Clarke A. Double trouble: are lupus and malignancy associated? Lupus 2001;10(6):388–91.

    Article  PubMed  CAS  Google Scholar 

  19. Valeriano J. Malignancy and rheumatic disease. Cancer Control 1997;4(3):236–44.

    PubMed  Google Scholar 

  20. Agudelo CA, Schumacher HR, Glick JH, Molina J. Non-Hodgkin’s lymphoma in systemic lupus Erythematosus: report of 4 cases with ultrastructural studies in 2. J Rheumatol 1981;8(1):69–78.

    PubMed  CAS  Google Scholar 

  21. Green JA, Dawson AA, Walker W. Systemic lupus Erythematosus and lymphoma. Lancet 1978;2(8093):753–6.

    Article  PubMed  CAS  Google Scholar 

  22. Yoinou P, Le Corre R, Dueymes M. Autoimmune diseases and monoclonal gammopathies. Clin Exp Rheumatol 1996;14 Suppl 14:55–8.

    Google Scholar 

  23. Rubin L, Urowitz MB, Pruzanski W. Systemic lupus Erythematosus with paraproteinemia. Arthritis Rheum 1984;27(6):638–44.

    Article  PubMed  CAS  Google Scholar 

  24. Kelly C, Baird G, Foster H, Hosker H, Griffiths I. Prognostic significance of paraproteinemia in rheumatoid arthritis. Ann Rheum Dis 1991;50(5):290–4.

    Article  PubMed  CAS  Google Scholar 

  25. Schafer AI, Miller JB. Association of IgA multiple myeloma with pre-existing disease. Br J Haematol 1979;41(1):19–24.

    PubMed  CAS  Google Scholar 

  26. Facon T, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97(6):1566–71.

    Article  PubMed  CAS  Google Scholar 

  27. Fonseca R, Oken MM, Greipp RP. Eastern Cooperative Oncology Group Myeloma Group. The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 2001;98(4):1271–2.

    Article  PubMed  CAS  Google Scholar 

  28. Avet-Loiseau H, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998;58(24):5640–5.

    PubMed  CAS  Google Scholar 

  29. Chang H, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004;125(1):64–8.

    Article  PubMed  Google Scholar 

  30. Jaksic W, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J C Oncol 2005;23(28):7069–73.

    Article  CAS  Google Scholar 

  31. Chesi M, et al. Frequent translocation t(4;14)(p16.3;q.32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genetics 1997;16(3):260–4.

    Article  CAS  Google Scholar 

  32. Richelda R, et al. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves fibroblast growth receptor 3 gene. Blood 1997;90(10):4062–70.

    PubMed  CAS  Google Scholar 

  33. Chesi M, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97(3):729–36.

    Article  PubMed  CAS  Google Scholar 

  34. Remmers EF, Sano H, Wider RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991;21(3):191–9.

    Article  PubMed  CAS  Google Scholar 

  35. Boumpas DT, Eleftheriades EG, Barez S, Tsokos GC. Oncogene expression and regulation in normal lymphocytes from patients with autoimmune disorders. Anticancer Res 1988;8(5A):977–84.

    PubMed  CAS  Google Scholar 

  36. Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. Overexpression of the myeloma associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood 2002;100(10):3819–21.

    Article  PubMed  CAS  Google Scholar 

  37. Brown RD, Pope B, Luo XF, Gibson J, Joshua D. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leuk Lymphoma 1994;16(1–2):147–56.

    Article  PubMed  CAS  Google Scholar 

  38. Standal T, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100(8):3002–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We would very much like to thank Dr Henry Dushan Edward Atkinson, Imperial College Medical School, St Mary’s Hospital, Praed Street, London, UK for his critical review and assistance in the writing of this paper in English.

Author information

Authors and Affiliations

  1. Institute of Hematology, Clinical Center of Serbia, 2, Koste Todorovic str., Belgrade, 11000, Serbia

    J. Bila, N. Suvajdzic, I. Elezovic, M. Colovic & D. Boskovic

Authors
  1. J. Bila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Suvajdzic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Elezovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Colovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Boskovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Bila.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bila, J., Suvajdzic, N., Elezovic, I. et al. Systemic lupus Erythematosus and IgA multiple myeloma: a rare association?. Med Oncol 24, 445–448 (2007). https://doi.org/10.1007/s12032-007-0047-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-007-0047-3

Keywords

Search

Navigation